ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 132,49
0,46%
Dow Jones
39 069,59
0,01%
DAX
18 774,71
0,43%
Brent Oil
82,905
0,07%
Bitcoin
69 301,23
-0,13%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) Actualités

NUVL

Nuvalent (NUVL)

Nuvalent Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NUVL
DateHeureSourceTitreSymboleSociété
17/05/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
16/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
16/05/202422h01PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655NASDAQ:NUVLNuvalent Inc
09/05/202412h46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NUVLNuvalent Inc
09/05/202412h30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/04/202422h30PR Newswire (US)Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
05/03/202422h52PR Newswire (US)Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
27/02/202413h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NUVLNuvalent Inc
27/02/202412h42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NUVLNuvalent Inc
27/02/202412h30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NUVLNuvalent Inc
27/02/202412h15PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520NASDAQ:NUVLNuvalent Inc
12/02/202412h30PR Newswire (US)Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid TumorsNASDAQ:NUVLNuvalent Inc
01/02/202412h30PR Newswire (US)Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NUVLNuvalent Inc
08/01/202412h30PR Newswire (US)Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated MilestonesNASDAQ:NUVLNuvalent Inc
26/12/202322h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
21/12/202312h30PR Newswire (US)Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
14/11/202312h30PR Newswire (US)Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsNASDAQ:NUVLNuvalent Inc
01/11/202311h30PR Newswire (US)Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology DayNASDAQ:NUVLNuvalent Inc
17/10/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NUVLNuvalent Inc
17/10/202303h55PR Newswire (US)Nuvalent Announces Pricing of Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
16/10/202313h30PR Newswire (US)Nuvalent Announces Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
13/10/202312h30PR Newswire (US)Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLCNASDAQ:NUVLNuvalent Inc
04/10/202318h21PR Newswire (US)Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety ProfileNASDAQ:NUVLNuvalent Inc
18/09/202312h30PR Newswire (US)Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC SymposiumNASDAQ:NUVLNuvalent Inc
05/09/202312h30PR Newswire (US)Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid TumorsNASDAQ:NUVLNuvalent Inc
31/08/202312h30PR Newswire (US)Nuvalent to Participate in Upcoming September Investor ConferencesNASDAQ:NUVLNuvalent Inc
10/08/202312h30PR Newswire (US)Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:NUVLNuvalent Inc
01/08/202312h30PR Newswire (US)Nuvalent to Participate in Upcoming August Investor ConferencesNASDAQ:NUVLNuvalent Inc
20/06/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NUVLNuvalent Inc
16/06/202322h58Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:NUVLNuvalent Inc
 Showing the most relevant articles for your search:NASDAQ:NUVL

Dernières Valeurs Consultées

AMEX
FNTC
Direxion Daily Fintech B...
NASDAQ
AAYIZXX
Bofa Finance Llc Issuer ...
NYSE
ARNC.PRB
Arconic Inc.
LSE
ABO
USOTC
GELGF
Chatham Rock Phosphate (PK)
LSE
50MK
Pension Ins 30
EU
3476S
3476S
USOTC
CNLMF
Collective Mining (QX)
COIN
PDCTTBTC
Premium Digi Coin
ASX
WRMNF
White Rock Minerals
BOV
OPIM11
Opportunity Fundo Invest...
COIN
HETAEUR
HetaChain Token
EU
7639T
7639T
USOTC
HMLSF
Global X Marijuana Life ... (CE)
LSE
TGBA
Tata Cons. 144a
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés